




# U.S. Food and Drug Administration



## CENTER FOR DRUG EVALUATION AND RESEARCH

[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)

- [CDER Home](#)
- [About CDER](#)
- [Drug Information](#)
- [Regulatory Guidance](#)
- [CDER Calendar](#)
- [Specific Audiences](#)
- [CDER Archives](#)

### Search



### This Guidance has been Finalized

Guidance for Industry: INDs — Approaches to Complying with CGMP During Phase 1 Draft Guidance <http://www.fda.gov/cder/guidance/6164dft.pdf> has been replaced.

The Final Version: entitled: Guidance for Industry: CGMP for Phase 1 Investigational Drugs can be accessed at: <http://www.fda.gov/cber/gdlns/indecmp.pdf>

[↑ Back to Top](#)   [↖ Back to Guidance Page](#)

PDF requires the free [Adobe Acrobat Reader](#)

Date created: November 3, 2008

---

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)  
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research